Megan Sarah Jean Arnold

Megan Sarah Jean Arnold

Auto-generated profile, based on publicly available information

Megan Sarah Jean Arnold

Griffith Institute for Drug Discovery, Griffith University, Queensland, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
MCMing Jang Chua
Ming Jang Chua
MAMegan S.J. Arnold
Megan S.J. Arnold
WXWeijun Xu
Weijun Xu
JLJulien Lancelot
Julien Lancelot
SLSuzanne Lamotte
Suzanne Lamotte
KAKatherine T. Andrews
Katherine T. Andrews
Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic diseases and each requires new innovative treatments. Targeting essential parasite pathways, such as those that regulate gene expression and cell cycle progression, is a key strategy for discovering new drug leads. In this study, four clinically approved anti-cancer drugs (Vorinostat, Belinostat, Panobinostat and Romidepsin) that target histone/lysine deacetylase enzymes were examined for in vitro activity against Plasmodium knowlesi, Schistosoma mansoni, Leishmania amazonensis and L. donovani parasites and two for in vivo activity in a mouse malaria model. All four compounds were potent inhibitors of P. knowlesi malaria parasites (IC50 9-370 nM), with belinostat, panobinostat and vorinostat having 8-45 fold selectivity for the parasite over human neonatal foreskin fibroblast (NFF) or human embryonic kidney (HEK 293) cells, while romidepsin was not selective. Each of the HDAC inhibitor drugs caused hyperacetylation of P. knowlesi histone H4. None of the drugs was active against Leishmania amastigote or promastigote parasites (IC50 > 20 μM) or S. mansoni schistosomula (IC50 > 10 μM), however romidepsin inhibited S. mansoni adult worm parings and egg production (IC50 ∼10 μM). Modest in vivo activity was observed in P. berghei infected mice dosed orally with vorinostat or panobinostat (25 mg/kg twice daily for four days), with a significant reduction in parasitemia observed on days 4-7 and 4-10 after infection (P < 0.05), respectively.

13 January 2016 in International Journal of Food Science and Technology
Verified
Journal Article
Closed access
PDF file
MWMitchell Henry Wright
Mitchell Henry Wright
BMBen Matthews
Ben Matthews
MAMegan Sarah Jean Arnold
Megan Sarah Jean Arnold
AGAnthony Carlson Greene
Anthony Carlson Greene
Ian Edwin CockIan Edwin Cock
Ian Edwin Cock

1 June 2016 in Pharmacognosy Communications
Verified
Journal Article
Open access
PDF file
CLCameron Jay Lee
Cameron Jay Lee
MWMitchell Henry Wright
Mitchell Henry Wright
MAMegan Sarah Jean Arnold
Megan Sarah Jean Arnold
AGAnthony Carlson Greene
Anthony Carlson Greene
Ian Edwin CockIan Edwin Cock
Ian Edwin Cock
Introduction: Streptococcus pyogenes can cause a variety of diseases including streptococcal pharyngitis, impetigo and rheumatic heart disease, dependant on which tissue it infects. Many Australian plants have documented therapeutic properties as general antiseptics, but are yet to be tested for the ability to inhibit S. pyogenes growth. Methods: Solvent extracts were prepared using Australian plants with documented ethnobotanical usage to treat bacterial infections, or published antibacterial activity. The extracts were investigated by disc diffusion assay for the ability to inhibit the growth of a clinical strain of S. pyogenes. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: S. pyogenes growth was inhibited by 24 of the 34 extracts tested. The Eucalyptus spp. extracts were particularly potent. MIC values of 341 and 88 µg/ mL were determined for the aqueous and methanolic E. baileyana extracts respectively. Similarly, MIC values of 134 and 53 µg/mL were determined for the aqueous and methanolic E. major extracts respectively. The methanolic wattle seed extract, aqueous and methanolic lemon aspen extracts, aqueous native thyme extract, methanolic river mint extract and the methanolic native basil extract were similarly potent growth inhibitors, with MIC values ≤1000 µg/mL. Several other extracts (methanolic native tamarind, bush tomato, desert lime, native thyme, native sage and the T. stipitata leaf extracts, as well as the aqueous river mint, native basil, T. stipitata leaf extracts) displayed moderate growth inhibitory activity (MIC=1000-5000 µg/mL). All other extracts were either low potency S. pyogenes growth inhibitors or were devoid of inhibitory activity. The E. baileyana and E. major methanolic extracts, as well as the E. baileyana aqueous extract induced significant mortality in the Artemia fransiscana bioassay, with LC 50 values substantially 1000 µg/mL. Conclusion: The potent growth inhibitory bioactivity of the Eucalyptus spp., lemon aspen, wattle seed, native basil and river mint extracts against S. pyogenes demonstrates their potential for the treatment and prevention of S. pyogenes induced disease. However, the toxicity of the Eucalyptus spp. extracts may limit their use to topical treatments for pharyngitis and impetigo. As the lemon aspen, wattle seed, native basil and river mint extracts were nontoxic, they may also have wider uses in treating systemic illnesses such as rheumatic fever, rheumatic heart disease and cellulitis.

1 April 2016 in Pharmacognosy Communications
Verified
Journal Article
Open access
PDF file
MWMitchell Henry Wright
Mitchell Henry Wright
MAMegan Sarah Jean Arnold
Megan Sarah Jean Arnold
CLCameron Jay Lee
Cameron Jay Lee
RCReece Courtney
Reece Courtney
AGAnthony Carlson Greene
Anthony Carlson Greene
Ian Edwin CockIan Edwin Cock
Ian Edwin Cock
Introduction: Streptococcus pyogenes is a gram-positive, pathogenic bacterium which causes a variety of diseases including streptococcal pharyngitis, impetigo and rheumatic heart disease, depending on which tissue it infects. Many Terminalia spp. have documented therapeutic properties as general antiseptics, inhibiting the growth of a wide variety of bacterial species. Methods: Solvent extracts were prepared using Indian Terminalia spp. with documented ethnobotanical usage to treat bacterial infections, or published antibacterial activity. The extracts were investigated by disc diffusion assay for the ability to inhibit the growth of a clinical strain of S. pyogenes. Their MIC values were determined to quantify and compare their efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: T. arjuna, T. catappa and T. chebula methanolic and ethyl acetate extracts displayed potent antibacterial activity in the disc diffusion assay against S. pyogenes. The T. catappa and T. chebula ethyl acetate extracts were particularly potent, with MIC values of 225 and 205 µg/mL respectively. All methanolic extracts were also potent growth inhibitors with MIC values of 268 µg/mL (T. arjuna methanolic extract), 425 µg/mL (T. catappa methanolic extract) and 300 µg/mL (T. chebula methanolic extract). The T. catappa hexane extract was also a potent S. pyogenes growth inhibitor (MIC 768 µg/mL). All other extracts were either ineffective or were of only low efficacy. Furthermore, all of the Indian Terminalia spp. extracts were nontoxic in the Artemia fransiscana bioassay, with LC 50 values >1000 µg/mL. Conclusion: The potent growth inhibitory bioactivity of the methanolic and ethyl acetate T. arjuna, T. catappa and T. chebula extracts against S. pyogenes demonstrates their potential for the treatment and prevention of pharyngitis, impetigo and rheumatic heart disease. All extracts were nontoxic indicating their safety for therapeutic use.

1 April 2017 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
GFGillian M. Fisher
Gillian M. Fisher
SBSilvia Bua
Silvia Bua
SPSonia Del Prete
Sonia Del Prete
MAMegan S.J. Arnold
Megan S.J. Arnold
Clemente CapassoClemente Capasso
Clemente Capasso
SPSally-Ann Poulsen
Sally-Ann Poulsen
In the past decade there has been a significant reduction in deaths due to malaria, in part due to the success of the gold standard antimalarial treatment - artemisinin combination therapies (ACTs). However the potential threat of ACT failure and the lack of a broadly effective malaria vaccine are driving efforts to discover new chemical entities (NCEs) to target this disease. The primary sulfonamide (PS) moiety is a component of several clinical drugs, including those for treatment of kidney disease, glaucoma and epilepsy, however this chemotype has not yet been exploited for malaria. In this study 31 PS compounds sourced from the GlaxoSmithKline (GSK) Tres Cantos antimalarial set (TCAMS) were investigated for their ability to selectively inhibit the in vitro growth of Plasmodium falciparum asexual stage malaria parasites. Of these, 14 compounds were found to have submicromolar activity (IC50 0.16-0.89 μM) and a modest selectivity index (SI) for the parasite versus human cells (SI > 12 to >43). As the PS moiety is known to inhibit carbonic anhydrase (CA) enzymes from many organisms, the PS compounds were assessed for recombinant P. falciparum CA (PfCA) mediated inhibition of CO2 hydration. The PfCA inhibition activity did not correlate with antiplasmodial potency. Furthermore, no significant difference in IC50 was observed for P. falciparum versus P. knowlesi (P > 0.05), a Plasmodium species that is not known to contain an annotated PfCA gene. Together these data suggest that the asexual intraerythrocytic stage antiplasmodial activity of the PS compounds examined in this study is likely unrelated to PfCA inhibition.

1 July 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MAMegan S. J. Arnold
Megan S. J. Arnold
JEJessica A. Engel
Jessica A. Engel
MCMing Jang Chua
Ming Jang Chua
GFGillian M. Fisher
Gillian M. Fisher
TSTina S Skinner-Adams
Tina S Skinner-Adams
KAKatherine T. Andrews
Katherine T. Andrews
The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [ 3 H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC 50 s) consistent with those obtained with P. falciparum . This assay provides a platform to use P. knowlesi in vitro for drug discovery.